{"id":22444,"date":"2015-10-27T10:59:55","date_gmt":"2015-10-27T09:59:55","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=22444"},"modified":"2015-10-27T11:36:40","modified_gmt":"2015-10-27T10:36:40","slug":"caduta-dellutile-di-novartis","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/caduta-dellutile-di-novartis\/","title":{"rendered":"Novartis profit drop"},"content":{"rendered":"<p><em>Contraction of 42% in the third quarter. Pharma giant talks about &#039;exceptional effects&#039;<\/em><\/p>\n<p><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/www.rsi.ch\/news\/economia\/Caduta-dellutile-di-Novartis-6321955.html\" target=\"_blank\" rel=\"noopener\">Tuesday 27\/10\/15 \u2013 RSI NEWS<\/a><\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.stoffe.ch\/stofftraum\/images\/novartis.jpg\" alt=\"\" width=\"278\" height=\"185\" \/>Novartis faces sharp fall in profit. For the third quarter of the year, it stood at 1.8 billion francs, an annual decrease of 42%.<\/p>\n<p>According to the pharmaceutical industry giant, this decline can be explained by &quot;exceptional elements&quot;: the company cites in this sense an extraordinary gain obtained in 2014 thanks to a sale of shares, as well as the creation of a commission intended for the costs of legal disputes.<\/p>\n<p>However, a decrease was also recorded in terms of turnover: the company&#039;s turnover fell by 6% and currently reaches a total of 12.3 billion dollars.<\/p>\n<p>Related news:\u00a0<a href=\"http:\/\/finanza.lastampa.it\/Notizie\/0,745334\/Novartis_sconta_le_sanzioni_Usa_ma_la_trimestrale.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Novartis discounts the US sanctions but the quarterly is still below the consensus<\/span><\/a><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Contrazione del 42% nel terzo trimestre. Il gigante farmaceutico parla di &#8220;effetti eccezionali&#8221; marted\u00ec 27\/10\/15 \u2013 RSI NEWS Novartis deve confrontarsi con una secca caduta dell&#8217;utile. Esso si attesta, per il terzo trimestre dell&#8217;anno, a 1,8 miliardi di franchi, con una diminuzione su base annuale del 42%. Secondo il gigante dell&#8217;industria farmaceutica, tale flessione si &hellip;<\/p>","protected":false},"author":4,"featured_media":2948,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[47],"class_list":["post-22444","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-big-pharma"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/22444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=22444"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/22444\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/2948"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=22444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=22444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=22444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}